[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Abroad (travel likely)RecruitingPHASE1
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Breast Cancer
Locations
- UCLA Jonsson Comp Cancer Center, Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- University of Kansas Medical Center, Westwood, Kansas, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Utah Intermountain Medical Center, Murray, Utah, United States
- Novartis Investigative Site, Guangzhou, China
- Novartis Investigative Site, Shanghai, China
- Novartis Investigative Site, Tianjin, China
- Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France
- Novartis Investigative Site, Bordeaux, France
- Novartis Investigative Site, Clermont-Ferrand, France
- Novartis Investigative Site, Saint-Herblain, France
- Novartis Investigative Site, Strasbourg, France
- Novartis Investigative Site, Cologne, Germany
- Novartis Investigative Site, Erlangen, Germany
- Novartis Investigative Site, Essen, Germany
- Novartis Investigative Site, München, Germany
- Novartis Investigative Site, Gliwice, Poland
- Novartis Investigative Site, Porto, Portugal
- Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain
- Novartis Investigative Site, Barcelona, Catalonia, Spain
- Novartis Investigative Site, Barcelona, Spain
- Novartis Investigative Site, Madrid, Spain
- Novartis Investigative Site, Madrid, Spain